OpenFold, a non-profit AI research consortium dedicated to creating free, open-source software tools for biology and drug discovery, announced today eight new industry partners. Joining the consortium are Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk, Structure Therapeutics, Tamarind Bio, Unnatural Products, and Visterra, each bringing valuable expertise and a shared commitment to harnessing AI technologies to accelerate drug discovery. With these additions, OpenFold continues to expand its collaborative network of academic and industry leaders for the advancement of open-source AI in molecular sciences.
“Each new member enhances OpenFold’s mission to drive innovation and collaboration in AI-powered drug discovery and industrial biotechnology. By developing tools accessible to everyone—from aspiring students to top biotech and pharmaceutical companies—we are collectively advancing the development of transformative medicines through state-of-the-art technologies and joint research initiatives,” said Alexandre Zanghellini, co-founder and CEO of Arzeda and an Executive Committee member of OpenFold Consortium.
Since its founding, OpenFold Consortium has released high-impact open-source artificial intelligence algorithms including the OpenFold protein structure prediction software, OpenFold-SoloSeq for rapid structural prediction that circumvents the need for multiple sequence alignments, and OpenFold-Multimer for prediction of protein-protein interactions. These community-driven tools have been widely-adopted by both academic and industry researchers, growing the consortium’s open-source ecosystem for structural biology and AI-driven drug discovery.
OpenFold was founded in February 2022 as a supported project of the Open Molecular Software Foundation, a non-profit organization centered on the advancement of molecular sciences by building communities for open-source research software development. The new members join OpenFold’s founders and existing members, bringing the total membership to 24 member companies, six of which are global pharmaceutical firms, Arzeda, Astex Pharmaceuticals, Basecamp Research, Bayer, Biogen, CHARMM Therapeutics, Congruence Therapeutics, Cyrus Biotechnology, Dassault Systemes, Outpace, Polaris Quantum Biotech, Psivant Therapeutics, Puxano, SandboxAQ, UCB, and Valence Labs, three supporting companies–Amazon Web Services, Microsoft, and NVIDIA, and two academic partnerships–Prof. Mohammed AlQuraishi’s Laboratory, Prof. Gabriel Rocklin’s Laboratory.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!